Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD pivotal phase 3 study in alcohol-induced liver decompensation
2015-004529-14Phase 3Terminated
- Sponsor
- Vital Therapies, Inc.
- Start
- Nov 2015
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ELAD in alcoholic liver disease (ALD) (2 arms), sponsored by Vital Therapies, Inc. Primary endpoint: Overall survival. Started Nov 2015; status: terminated.
02
Drugs
ELAD
03
Conditions
alcoholic liver disease (ALD)
Beyond the preview
Go deeper on 2015-004529-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004529-14.